Procedure success defined as ≤50% residual stenosis for all treated lesions without significant angiographic complications
DISRUPT BTK II
By The Numbers
Studies a real-world CLI patient population, including patients with long, calcified lesions.
Prospective, multi-center, core lab adjudicated.
Moderate-severe calcium assessed by angiography or IVUS.
IVL is the definitive treatment.
Secondary Endpoints: Primary Patency, Clinically Relevant TLF, ABI/TBI & RC, QoL, Wound Healing.
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.